Literature DB >> 16187554

Pharmacokinetics of difloxacin and its concentration in body fluids and endometrial tissues of mares after repeated intragastric administration.

Aric R Adams1, Gregory R Haines, Murray P Brown, Ronald Gronwall, Kelly Merritt.   

Abstract

Pharmacokinetics of difloxacin and its distribution within the body fluids and endometrium of 6 mares were studied after intragastric (IG) administration of 5 individual doses. Difloxacin concentrations were serially measured in serum, urine, peritoneal fluid, synovial fluid, cerebrospinal fluid, and endometrium over 120 h. Bacterial susceptibility to difloxacin was determined for 174 equine pathogens over a 7-month period. Maximum serum concentration (Cmax) was 2.25 +/- 0.70 microg/mL at 3.12 +/- 2.63 h and Cmax after the 5th dose was 2.41 +/- 0.86 microg/mL at 97.86 +/- 1.45 h. The mean elimination half-life (t(1/2)) was 8.75 +/- 2.77 h and area under the serum concentration versus time curve (AUC) was 25.13 +/- 8.79 microg h/mL. Highest mean synovial fluid concentration was 1.26 +/- 0.49 microg/mL at 100 h. Highest mean peritoneal fluid concentration was 1.50 +/- 0.56 microg/mL at 98 h. Highest mean endometrial concentration was 0.78 +/- 0.48 microg/g at 97.5 h. Mean cerebrospinal fluid concentration was 0.87 +/- 0.52 microg/mL at 99 h. Highest mean urine concentration was 92.05 +/- 30.35 microg/mL at 104 h. All isolates of Salmonella spp. and Pasteurella spp. were susceptible. In general, gram-negative organisms were more susceptible than gram-positives. Difloxacin appears to be safe, adequately absorbed, and well distributed to body fluids and endometrial tissues of mares and may be useful in the treatment of susceptible bacterial infections in adult horses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16187554      PMCID: PMC1176303     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  29 in total

1.  Serum concentrations and pharmacokinetics of enrofloxacin after intravenous and intragastric administration to mares.

Authors:  G R Haines; M P Brown; R R Gronwall; K A Merritt
Journal:  Can J Vet Res       Date:  2000-07       Impact factor: 1.310

2.  In vitro activity of difloxacin against canine bacterial isolates.

Authors:  R van den Hoven; J A Wagenaar; R D Walker
Journal:  J Vet Diagn Invest       Date:  2000-05       Impact factor: 1.279

3.  Decrease in antibiotic susceptibility or increase in resistance?

Authors:  R D Walker; C Thornsberry
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

Review 4.  Disposition of single-dose oral enrofloxacin in the horse.

Authors:  V C Langston; S Sedrish; D M Boothe
Journal:  J Vet Pharmacol Ther       Date:  1996-08       Impact factor: 1.786

Review 5.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

6.  Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin, and difloxacin in dogs.

Authors:  D L Frazier; L Thompson; A Trettien; E I Evans
Journal:  J Vet Pharmacol Ther       Date:  2000-10       Impact factor: 1.786

7.  Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares.

Authors:  G R Haines; M P Brown; R R Gronwall; K A Merritt; L K Baltzley
Journal:  Can J Vet Res       Date:  2001-07       Impact factor: 1.310

8.  Efficacy of difloxacin in calves experimentally infected with Mannheimia haemolytica.

Authors:  T W Olchowy; T N TerHune; R L Herrick
Journal:  Am J Vet Res       Date:  2000-06       Impact factor: 1.156

9.  Pharmacokinetics of enrofloxacin in adult horses and concentration of the drug in serum, body fluids, and endometrial tissues after repeated intragastrically administered doses.

Authors:  S Giguère; R W Sweeney; M Bélanger
Journal:  Am J Vet Res       Date:  1996-07       Impact factor: 1.156

10.  Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections.

Authors:  J B Meinen; J T McClure; E Rosin
Journal:  Am J Vet Res       Date:  1995-09       Impact factor: 1.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.